SCHEMBL15480550

SCHEMBL15480550

O=C(NO)c1ccc(NS(=O)(=O)c2ccc3ccccc3c2)cc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.73
SMN1; SMN2 Q16637 2/20 0.73
ALDH1A1 P00352 2/20 0.73
GAA P10253 1/20 0.73
HDAC1 Q13547 2/20 0.65
PLAU P00749 2/20 0.65
GPR27 Q9NS67 1/20 0.64
ATM Q13315 1/20 0.63
HDAC8 Q9BY41 4/20 0.62
HDAC6 Q9UBN7 4/20 0.62
HDAC3 O15379 3/20 0.62
HDAC11 Q96DB2 3/20 0.62
HDAC2 Q92769 2/20 0.62
HDAC4 P56524 1/20 0.62
HDAC7 Q8WUI4 1/20 0.62
HDAC10 Q969S8 1/20 0.62
HDAC9 Q9UKV0 1/20 0.62
HDAC5 Q9UQL6 1/20 0.62
PGR P06401 1/20 0.60
AKR1C3 P42330 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7782154 0.86 ALDH1A1 (0.77) LMNASMN1; SMN2ALDH1A1GAAHDAC1
SCHEMBL8275407 0.84 ALDH1A1 (1.00) LMNASMN1; SMN2ALDH1A1GAAHDAC1
SCHEMBL12525609 0.82 HDAC6 (0.63) LMNASMN1; SMN2ALDH1A1GAAHDAC8
SCHEMBL15480563 0.82 HDAC6 (0.60) LMNASMN1; SMN2ALDH1A1GAAHDAC1
SCHEMBL15480538 0.82 MEN1 (0.71) SMN1; SMN2ALDH1A1HDAC1HDAC8HDAC6
SCHEMBL8276342 0.81 HDAC1 (0.70) LMNASMN1; SMN2ALDH1A1GAAHDAC1
SCHEMBL808105 0.81 ATM (0.72) LMNASMN1; SMN2ALDH1A1GAAHDAC1
SCHEMBL20021984 0.81 ATM (0.72) LMNASMN1; SMN2ALDH1A1GAAHDAC1
SCHEMBL15480556 0.81 HDAC6 (0.59) LMNASMN1; SMN2ALDH1A1GAAHDAC1
SCHEMBL20021987 0.80 PGR (0.77) LMNASMN1; SMN2ALDH1A1GAAHDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210060014-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS CERENO SCIENTIFIC AB (SE) 2021-03-04 US disclosed
US-20170020874-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS CERENO SCIENT AB (SE) 2017-01-26 US disclosed
US-20140051716-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS CERENO SCIENTIFIC AB 2014-02-20 US disclosed
US-20140051716-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS CERENO SCIENTIFIC AB 2014-02-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140051716-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS HDAC3, HDAC1, HDAC2 LMNA 489/4885SMN1; SMN2 2901/4885ALDH1A1 3068/4885
US-20170020874-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS HDAC3, HDAC1, HDAC2 LMNA 489/4885SMN1; SMN2 2901/4885ALDH1A1 3068/4885
US-20210060014-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS HDAC3, HDAC1, HDAC2 LMNA 489/4885SMN1; SMN2 2901/4885ALDH1A1 3068/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.